News for BioMarin Pharmaceutical Inc. (BMRN)

Insight into Biomarin's robust product portfolio and expanding pipeline.Analysis of Biomarin's financial resilience and strategic growth initiatives.Understand

PR NewswireSAN RAFAEL, Calif., Feb. 24, 2025 SAN RAFAEL, Calif., Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ETCompany ParticipantsTraci McCarty - Head of...

BioMarin (BMRN) delivered earnings and revenue surprises of 26.03% and 4.97%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The following slide deck was published by BioMarin Pharmaceutical Inc.

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Is BioMarin stock a bargain or a falling knife? Learn about key issues affecting its investment prospects and potential for recovery.

We recently compiled a list of the Billionaire Andreas Halvorsen's Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical are part of the Zacks Screen of the Week article.

BioMarin Pharmaceutical Inc (BMRN) announced on January 6, 2025, that its President and CEO, Alexander Hardy, will present at the 43rd Annual J.P. Morgan Health

PR NewswireSAN RAFAEL, Calif., Jan. 6, 2025 SAN RAFAEL, Calif., Jan. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced th

A new year brings with it new opportunities to grow your wealth on Wall Street.

Sangamo Therapeutics Inc. shares fell the most in 16 years after Pfizer Inc. ended the two companies’ partnership to develop a new gene therapy to treat hemophilia A. Sangamo is considering “all options” to continue developing the drug, including finding a new partner, the company said in a statement Monday.…

Sangamo Therapeutics Inc. (SMO), a genomic medicine company, experienced a major setback as Pfizer Inc. (PFE) terminated their collaboration on a groundbreaking gene therapy for hemophilia A. The abrupt end to this partnership triggered Sangamo’s largest single-day share drop in more than 15 years. The decision came unexpectedly, with Sangamo's…

212 firms in the S&P 1500 have not beaten even US treasuries over the last 10 years